A detailed history of Sofinnova Investments, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Sofinnova Investments, Inc. holds 26,800 shares of ACAD stock, worth $643,736. This represents 0.03% of its overall portfolio holdings.

Number of Shares
26,800
Holding current value
$643,736
% of portfolio
0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

BUY
$20.88 - $26.57 $559,584 - $712,076
26,800 New
26,800 $571,000
Q1 2021

May 14, 2021

SELL
$25.02 - $54.99 $4.12 Million - $9.05 Million
-164,625 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$41.04 - $56.79 $4.75 Million - $6.57 Million
115,629 Added 236.0%
164,625 $8.8 Million
Q3 2020

Nov 13, 2020

BUY
$36.42 - $57.0 $1.78 Million - $2.79 Million
48,996 New
48,996 $2.02 Million
Q3 2019

Nov 14, 2019

SELL
$22.22 - $44.01 $3.46 Million - $6.85 Million
-155,576 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$23.32 - $28.12 $3.63 Million - $4.37 Million
155,576 New
155,576 $4.16 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $3.89B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Sofinnova Investments, Inc. Portfolio

Follow Sofinnova Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.